Cytek Biosciences, Inc.
CTKBNASDAQHealthcare● Active
$4.04
$-0.05(-1.22%)
Market Cap$521736051
P/E Ratio—
52W High$6.18
52W Low$2.9
Cytek Biosciences, Inc. (CTKB) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CTKB · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.20B | $0.20B | $0.19B | $0.16B | $0.13B |
| Cost of Revenue | $0.10B | $0.09B | $0.08B | $0.06B | $0.05B |
| Gross Profit | $0.10B | $0.11B | $0.11B | $0.10B | $0.08B |
| Gross Margin %(computed) | 51.84% | 55.43% | 56.69% | 61.56% | 61.86% |
| Operating Expenses | |||||
| R&D Expenses | $0.04B | $0.04B | $0.04B | $0.03B | $0.02B |
| G&A Expenses | $0.06B | $0.04B | $0.04B | $0.03B | $0.02B |
| Total Operating Expenses | $0.14B | $0.13B | $0.14B | $0.10B | $0.07B |
| Operating Income | ($0.04B) | ($0.02B) | ($0.03B) | ($0.00B) | $0.01B |
| Operating Margin %(computed) | -20.04% | -10.24% | -14.43% | -1.10% | 7.16% |
| Interest Income | $0.00B | $0.01B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.03B) | ($0.01B) | ($0.02B) | $0.00B | $0.01B |
| Income Tax Expense | $0.04B | $0.00B | ($0.00B) | ($0.00B) | $0.00B |
| Net Income | ($0.07B) | ($0.01B) | ($0.01B) | $0.00B | $0.00B |
| Net Margin %(computed) | -33.02% | -3.00% | -6.29% | 1.57% | 2.35% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.52 | $-0.05 | $-0.09 | $0.02 | $0.03 |
| Wtd Avg Shares | 0.13B | 0.13B | 0.14B | 0.13B | 0.13B |
| EBITDA | ($0.02B) | ($0.01B) | ($0.00B) | $0.01B | $0.01B |
| EBITDA Margin %(computed) | -8.63% | -5.01% | -2.28% | 5.79% | 6.97% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Cytek Biosciences, Inc. data
About Cytek Biosciences, Inc. (CTKB) Income Statement
Cytek Biosciences, Inc. (CTKB) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CTKB reported revenue of $0.20B, gross profit of $0.10B (gross margin 51.84%), and net income of ($0.07B) — a net profit margin of -33.02%.
Frequently asked questions
CTKB · 4 questionsCytek Biosciences, Inc. (CTKB) reported revenue of $0.20B for 2025, up 0.5% year-over-year.
CTKB revenueCTKB salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08